---
title: "Sensei Biotherapeutics IncQ) expected to post a loss of $5.60 a share - Earnings Preview"
description: "Sensei Biotherapeutics IncQ) is projected to report a loss of $5.60 per share for the quarter ending June 30, 2025, with no change in quarterly revenue. Analysts maintain a \"strong buy\" rating, with a"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251217398.md"
published_at: "2025-08-01T13:48:10.000Z"
---

# Sensei Biotherapeutics IncQ) expected to post a loss of $5.60 a share - Earnings Preview

> Sensei Biotherapeutics IncQ) is projected to report a loss of $5.60 per share for the quarter ending June 30, 2025, with no change in quarterly revenue. Analysts maintain a "strong buy" rating, with a median 12-month price target of $67.50, representing an 88.9% increase from the last closing price of $7.48. The mean earnings estimate has remained unchanged over the past three months.

-   Sensei Biotherapeutics Inc (SNSE.OQ) (SNSE.O) is expected to

show no change in quarterly revenue when it reports results on August 4 (estimated) for the period ending June 30 2025

-   ​LSEG’s mean analyst estimate for Sensei Biotherapeutics Inc is for a loss of $5.60 per share.
-   The current average analyst rating on the shares is “strong buy” and the breakdown of recommendations is 3 “strong buy” or “buy,” no “hold” and no “sell” or “strong sell.”
-   The mean earnings estimate of analysts was unchanged in the last three months. ​
-   Wall Street’s median 12-month price target for Sensei Biotherapeutics Inc is $67.50, about 88.9% above its last closing price of $7.48 This summary was machine generated August 1 at 13:48 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

### Related Stocks

- [SNSE.US - Sensei Biotherapeutics](https://longbridge.com/en/quote/SNSE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| James Peyer, 10% Owner, Sells Common Shares of Sensei Biotherapeutics Inc | James Peyer, a 10% owner of Sensei Biotherapeutics Inc., has sold common shares of the company. The transaction was repo | [Link](https://longbridge.com/en/news/268997664.md) |
| Sensei Biotherapeutics Sets New Executive Salaries and Retention Bonuses | Sensei Biotherapeutics Inc. has announced new retention agreements for its executives, effective November 14, 2025. Pres | [Link](https://longbridge.com/en/news/270658949.md) |
| 10% Owner James Peyer Reports Disposal of Sensei Biotherapeutics Inc. Common Shares | James Peyer, a 10% owner of Sensei Biotherapeutics Inc., reported the disposal of common shares of the company. The orig | [Link](https://longbridge.com/en/news/269289555.md) |
| Sensei Biotherapeutics Inc. Files Initial Statement of Beneficial Ownership for President & PEO Christopher Gerry | Sensei Biotherapeutics Inc. has filed an initial statement of beneficial ownership with the SEC, listing Christopher Ger | [Link](https://longbridge.com/en/news/267249806.md) |
| BUZZ-Sensei falls as it scraps cancer drug development, plans to sell itself | Shares of Sensei Biotherapeuticsfell after the company announced it will halt the development of its cancer drug solners | [Link](https://longbridge.com/en/news/263538715.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.